|Bid||82.81 x 800|
|Ask||82.99 x 800|
|Day's Range||82.39 - 83.69|
|52 Week Range||43.30 - 90.03|
|Beta (3Y Monthly)||1.13|
|PE Ratio (TTM)||13.58|
|Earnings Date||Feb 21, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||94.25|
Integer (ITGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Small and large cap stocks are widelyRead More...
Integer Holdings Corp NYSE:ITGRView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for ITGR with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ITGR. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding ITGR totaled $519 million. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
NEW YORK, Feb. 05, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Join Emerald Asset Management for the 26th annual Emerald Groundhog Day Investment Forum on February 7th in Philadelphia. Emerald’s team will be joined by noted economist Joel Naroff and senior executives from companies that exemplify the trends identified by Emerald and who will provide insights on the state of their industries and sectors. The Groundhog Day Investment Forum will be held on Thursday, February 7th at the DoubleTree by Hilton Hotel in Philadelphia, PA.
Today we are going to look at Integer Holdings Corporation (NYSE:ITGR) to see whether it might be an attractive investment prospect. In particular, we'll consider its Return On Capital Employed Read More...
PLANO, Texas, Jan. 15, 2019 -- Integer Holdings Corporation (NYSE:ITGR), announced today that it plans to release financial and operational results for fourth quarter and.
Patterson Companies (PDCO) gains from solid foothold in theAnimals Health business. However, the company is facing headwinds in the Dental segment.
Integer, a leading medical device outsource (MDO) manufacturer, today announced it has entered into a new development agreement and a new supply agreement with Respicardia, Inc., a medical technology company dedicated to developing innovative therapies that address unmet needs in respiratory and cardiovascular disease. Under the agreements, Integer will be Respicardia’s development partner and majority supplier of the remedē® implantable pulse generator (IPG) and related products for seven years, the first 5 ½ years as an exclusive supplier. “We’re honored to continue supporting Respicardia in bringing their therapy to market,” said Tony Gonzalez, president of Integer’s Cardiac Rhythm Management and Neuromodulation product line.
Omnicell (OMCL) steadily sees a solid uptake of Omnicell XT. It also strikes various deals for the XR2 and IVX Workflow products.
CVS Health (CVS) is optimistic about synergies from Aetna deal which will help create a robust platform to serve individuals better.
Per NuVasive (NUVA), the international region holds significant growth opportunity. However, pricing pressure is a major headwind.
Focus on emerging markets, improving margins and encouraging guidance provide PerkinElmer (PKI) a competitive edge in the MedTech space.
Amedisys (AMED) is developing and acquiring new business lines that will complement its existing home care and hospice business.
We are upbeat about Walgreens' (WBA) recent pact with Alphabet???s life sciences and healthcare segment, Verily, to coordinate on multiple projects with respect to chronic ailments.